US Patent

US12128039 — Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds

Method of Use · Assigned to Exelixis Inc · Expires 2032-02-10 · 6y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects processes for making and compositions containing quinoline compounds, including CABOZANTINIB S-MALATE, and their pharmaceutically acceptable salts.

USPTO Abstract

The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1220 — cabozantinib-s-malate
U-1617 — cabozantinib-s-malate
U-1617 — cabozantinib-s-malate
U-1220 — cabozantinib-s-malate
U-1220 — cabozantinib-s-malate

Patent Metadata

Patent number
US12128039
Jurisdiction
US
Classification
Method of Use
Expires
2032-02-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Exelixis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.